Description
RKI-1313 weak inhibitor for ROCK2-dependent signaling and has less effect on phosphorylation levels of ROCK substrates. RKI-1313 serves as a negative control for RKI-1447 (Cat. No. 2472) which is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer.
RKI-1313 weak inhibitor for ROCK2-dependent signaling and has less effect on phosphorylation levels of ROCK substrates. RKI-1313 serves as a negative control for RKI-1447 (Cat. No. 2472) which is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer.
Alternate Name/Synonyms: 1-(3-Methoxybenzyl)-3-[4-(pyridin-4-yl)thiazol-2-yl]urea
Appearance: Crystalline solid
Formulation: N/A
CAS Number: 1342276-76-9
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₁₇H₁₆N₄O₂S
Molecular Weight: 340.4
Cell-Permeable?: Yes
Purity: ≥98% by HPLC
Solubilities: DMSO
Handling: Protect from air and light
Country of Origin: USA
Tag Line: A useful negative control for RKI-1447 (Cat.No. 2472)
MDL Number: N/A
PubChem CID: 53492330
SMILES: COC1=CC=CC(=C1)CNC(=O)NC2=NC(=CS2)C3=CC=NC=C3
InChi: InChI=1S/C17H16N4O2S/c1-23-14-4-2-3-12(9-14)10-19-16(22)21-17-20-15(11-24-17)13-5-7-18-8-6-13/h2-9,11H,10H2,1H3,(H2,19,20,21,22)
InChi Key: BDCUKYUIVYKXCQ-UHFFFAOYSA-N
Additional Information
Storage Condition: |
-20°C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |